Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Other long-term liabilities | 15,406 | 7,439 |
| Net cash provided by operating activities | 97,394 | 50,414 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (824) | (264) |
| Purchases of short-term investments | (287,031) | (129,793) |
| Proceeds from the maturities of short-term investments | 182,359 | 74,633 |
| Net cash used in investing activities | (105,496) | (55,424) |
| Cash flows from financing activities: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's capex?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported capex of $663K in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's capex changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's capex increased by 301.8% year-over-year, from $165K to $663K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's capex?
- Over 2 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's capex has grown at a 94.4% compound annual growth rate (CAGR), from $415K to $1.57M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Kiniksa Pharmaceuticals International, plc's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude